List of Tables

Tab 2.1 - Inflammatory Mediators and their Description

Tab 2.2 - The description and method of calculation of some important QSAR parameters.

Tab 2.3 - Successful molecules derived from QSAR.

Tab 4.1 - Physicochemical characteristics of 2-substituted-3,4-diphenyl-isoquinolone derivatives.

Tab 4.2 - Physicochemical characteristics of 2-substituted-3,4-diphenyl-2H benzo[1,2] thiazine1, 1-dioxide derivatives.

Tab 4.3 - Anti-inflammatory activity of Isoquinolone derivatives when administered orally at the dose of 100mg/kg by carrageenan induced rat paw edema method.

Tab 4.4 - Percentage inhibition of rat paw edema treated with Isoquinolone derivatives when administered orally at the dose of 100mg/kg.

Tab 4.5 - Anti-inflammatory activity of Benzothiazine derivatives when administered orally at the dose of 100mg/kg by carrageenan induced rat paw edema method.

Tab 4.6 - Percentage inhibition of rat paw edema treated with Benzothiazine derivatives when administered orally at the dose of 100mg/kg.

Tab 4.7 - Xylene induced topical anti-inflammatory activity for Isoquinolone derivatives.

Tab 4.8 - Xylene induced topical anti-inflammatory activity for Benzothiazine derivatives.

Tab 4.9 - Cotton pellet induced granuloma method for chronic anti-inflammatory activity on Isoquinolone derivatives.

Tab 4.10 - Cotton pellet induced granuloma method for chronic anti-inflammatory activity on Benzothiazine derivatives.

Tab 4.11 - Effect of Isoquinolone derivatives when administered orally at the dose of 100 mg/kg on E.coli LPS induced plasma cytokine levels in rat.
Tab 4.12 - Antiinflammatory activity of Benzothiazine derivatives when administered orally at the dose of 100 mg/kg on E.coli LPS induced plasma TNF-α levels in rat.

Tab 4.13 - Anti-arthritic activity of Isoquinolone derivatives when administered orally at the dose of 100mg/kg by formaldehyde induced arthritis method.

Tab 4.14 - Percentage inhibition rat paw edema by Isoquinolone derivatives when administered orally at the dose of 100mg/kg.

Tab 4.15 - Anti-arthritic activity of Benzothiazine derivatives when administered orally at the dose of 100mg/kg by formaldehyde induced arthritis model.

Tab 4.16 - Percentage inhibition rat paw edema by Isoquinolone derivatives when administered orally at the dose of 100mg/kg.

Tab 4.17 - Analgesic activity of Isoquinolone derivatives when administered orally at the dose of 100 mg/kg by acetic acid induced writhing in mice.

Tab 4.18 - Analgesic activity of Benzothiazine derivatives when administered orally at the dose of 100 mg/kg by acetic acid induced writhing in mice.

Tab 4.19 - Antimicrobial activity of Isoquinolone derivatives.

Tab 4.20 - Log MIC value of Antimicrobial activity of Isoquinolone derivatives.

Tab 4.21 - Antimicrobial activity of Isoquinolone derivatives

Tab 4.22 - Log MIC value of Antimicrobial activity of benzothiazine derivatives

Tab 4.23 - Biological activity for synthesized 3,4-diphenyl Benzothiazine derivatives.

Tab 4.24 - Values of selected descriptors used in the regression analysis.

Tab 4.25 - Correlation matrix for topical anti-inflammatory activity.

Tab 4.26 - Correlation of molecular descriptors with biological activity.

Tab 4.27 - Comparison of observed, predicted and residual biological activities.
List of Figures

Fig 2.1- Pathway of acute inflammation process.

Fig 2.2- Cytokines involved in acute and chronic inflammatory responses.

Fig 4.1- Percentage Inhibition of rat paw edema by Isoquinolone derivatives when administered orally at the dose of 100mg/kg by carrageenan induced rat hind paw edema method at 3 h.

Fig 4.2- Percentage Inhibition of rat paw edema by Benzothiazine derivatives when administered orally at the dose of 100mg/kg by carrageenan induced rat hind paw edema method at 3 h.

Fig 4.3- Xylene induced topical anti-inflammatory activity for Isoquinolone derivatives.

Fig 4.4- Xylene induced topical anti-inflammatory activity for Benzothiazine derivatives.

Fig 4.5- Cotton pellet induced granuloma method for chronic anti-inflammatory activity on Isoquinolone derivatives.

Fig 4.6- Cotton pellet induced granuloma method for chronic anti-inflammatory activity on Benzothiazine derivatives.

Fig 4.7- Effect of Isoquinolone derivatives when administered orally at the dose of 100 mg/kg on E.coli LPS induced plasma cytokine levels in rat.

Fig 4.8- Effect of Isoquinolone derivatives when administered orally at the dose of 100 mg/kg by E.coli LPS induced plasma cytokine levels on rat.

Figs 4.9- Percentage inhibition of rat paw edema by Isoquinolone derivatives when administered orally at the dose of 100mg/kg on day 1st, 3rd, 7th and 10th.
Fig 4.10- Percentage inhibition of rat paw edema by Benzothiazine derivatives when administered orally at the dose of 100mg/kg on day 1st, 3rd, 7th and 10th.

Fig 4.11- Histopathological slide of heart of Rat treated with JS13 and JS33

Fig 4.12- Histopathological slide of liver of Rat treated with JS13 and JS33

Fig 4.13- Histopathological slide of stomach of Rat treated with JS13 and JS33

Fig 4.14- Percentage inhibition of writhing by Isoquinolone derivatives when administered orally at the dose of 100 mg/kg by acetic acid induced writhing in mice.

Fig 4.15- Percentage inhibition of writhing by Benzothiazine derivatives when administered orally at the dose of 100 mg/kg by acetic acid induced writhing in mice.